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Ulrike Bacher,1 Claudia Haferlach,2 Nicolaus Kro¨ger,1 Susanne Schnittger,1 Wolfgang Kern,1
Bettina Wiedemann,1 Axel Rolf Zander,1 Torsten Haferlach2The rates of allogeneic stem cell transplantation (SCT) to treat the myelodysplastic syndromes (MDS) is con-
tinually increasing. However, given the growing arsenal of therapeutic options in parallel to deeper insight
into the heterogeneity of this disorder, determining the indications for SCT in MDS remains a difficult
task. The International Prognostic Scoring System (IPSS) serves as a guideline for therapeutic decisions,
but many aspects (eg, interpretation of rare cytogenetic abnormalities, combinations of chromosomal alter-
ations and/or molecular markers, variant clinical courses within distinct biological subgroups) remain the sub-
ject of continuous investigation. In an effort to achieve a more well-differentiated risk categorization,
attempts have been made to perform a more detailed cytogenetic categorization, and the use of various fluo-
rescein in situ hybridization (FISH) techniques has improved the description of aberrations. Multicenter ini-
tiatives have standardized multiparameter flow cytometry techniques for diagnosis of MDS. In advanced
MDS, screening for molecular mutations can identify cases with a high transformation risk. Finally, the
new World Health Organization classification system provides a more homogenous morphological catego-
rization of MDS compared with the former French-American-British system. Consequently, in the near fu-
ture, risk stratification in MDS might incorporate additional diagnostic tools and categorization systems
aimed at improving the timing and indication for SCT in this complex disorder.
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Based on phenotypic and genotypic aspects, the
myelodysplastic syndromes (MDS) are highly hetero-
geneous subentities. The spectrum ranges from stable
conditions with a near-normal standardized mortality
ratio (eg,. in refractory anemia with erythroid dysplasia
only) to entities that are very close to acute myeloge-
nous leukemia (AML) [1,2]. Therapeutic concepts in
MDS have been expanding recently [3]. In low-risk
cases, supportive strategies might be justified, whereas
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6/j.bbmt.2009.08.007apy regimens [4]. New compounds, such as hypome-
thylating agents [5], have been successfully
introduced. With the thalidomide-derivate lenalido-
mide for the 5q- syndrome [5,6], targeted therapy for
a specific MDS subtype has been realized. Finally, the
use of allogeneic stem cell transplantation (allo-SCT)
to treat MDS has been steadily increasing. Gratwohl
et al. [7] documented a 10% increase in annual allo-
SCTs from2001 to 2002 inEuropean centers [7], based
on, among other factors, the increased use of reduced-
intensity conditioning (RIC) [8-10].
Thus, therapeutic options for MDS have become
more diversified in terms of dependence on individual
subtypes and risk profiles, and the timing of allo-SCT
inMDS has become amajor task for hematologists and
transplantation specialists [2]. Using the International
Prognostic Scoring System (IPSS) criteria, patients
from the intermediate-2 and high risk groups had the
longest life expectancy when they underwent early
SCT, whereas those from the low and intermediate-1
risk groups received a benefit from delaying SCT for
several years [11,12]. On the other hand, the stage of
MDS at the time of allo-SCT significantly influences
the outcome of transplantation; lower stages are1
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ease-free survival (DFS) compared with intermediate
or advancedMDS [13], and delaying SCT is associated
with an increased risk of comorbidities or iron accu-
mulation [14,15].
So far, risk categorization in MDS has been based
on the results of cytomorphology and karyotyping.
But, the panel of diagnostic methods in MDS is con-
tinually expanding, with diverse fluorescein in situ
hybridization (FISH) techniques, such as 24-color
FISH and spectral karyotyping [16,17], and multipa-
rameter flow cytometry (MFC) finding diagnostic ap-
plications in this entity [18]. It remains to be clarified
whether additional techniques might become relevant
for the decision to SCT in this heterogeneous dis-
ease. This is illustrated by the question of whether
abnormal results of interphase FISH analysis should
be considered in therapeutic decisions when chromo-
some banding reveals a normal karyotype. Further-
more, regardless of the guidance of the IPSS with
respect to the categorization of frequent cytogenetic
aberrations (eg, of chromosome 7 [19]), the decision
for or against allo-SCT can raise difficulties in cases
with rare chromosomal abnormalities [20] or in cases
exhibiting a coincidence of a del(5q) with another
alteration [21]. For many cytogenetic alterations in
MDS, the clinical significance remains to be defined
[22]. For each of these genetic parameters, the prog-
nostic impact should be newly evaluated in light of
novel therapeutic approaches—for example, for
monosomy 7 in light of azacytidine [23]. Further-
more, the panel of genetic markers is expanding; mu-
tations or deletions of the TET2 tumor-suppressor
gene were recently detected in up to 26% of MDS
patients [24,25].
Despite recent advances, the clinical significance of
many parameters in the indications for SCT remains
controversial. This review focuses on the impact of di-
verse diagnostic techniques and discusses parameters
and methods that might become relevant to this com-
plex decision in the near future.CYTOMORPHOLOGY
Based on the French-American-British (FAB)
MDS classification system [26], in 2001 the World
Heath Organization (WHO) published a more differ-
entiated categorization, which has since been modified
(Table 1) [27]. In terms of the low-risk stages of MDS,
the 5q- syndrome with its more or less unique cyto-
morphologic profile and\5% of bone marrow (BM)
blasts still represents a distinct entity, but is now called
‘‘MDS with an isolated 5q- deletion.’’ Likewise, along
with refractory anemia (RA), the subtypes refractory
neutropenia (RN) and refractory thrombocytopenia
(RT) have been introduced. All of these subtypesnow belong to the category termed ‘‘refractory cytope-
nia with unilineage dysplasia’’ (RCUD). Refractory
anemia with ring sideroblasts (RARS) defines a specific
category because of the specific morphological fea-
tures with $15% of ring sideroblasts in combination
with related clinical features, including low leukemic
transformation rate (\ 5%) and a favorable median
OS of 5-9 years [28].
In contrast to these lower-risk stages, refractory cy-
topenia with multilineage dysplasia (RCMD), defined
by the presence of dysplastic features in at least 2 mye-
loid lineages, carries a leukemic transformation rate of
10% within 2 years and a median OS of only 30
months [28]. Cases with $15% ring sideroblasts and
multilineage dysplasia were previously classified as
RCMD-RS but are now combined with the RCMD
category, because the prognosis apparently does not
differ from that of pure RCMD cases [2,27,28].
Several studies have demonstrated concordantly
a significantly worse prognosis in cases of multilineage
dysplasia compared with cases involving only a single
lineage [16,29]. Navarro et al. [30] reported that in
311 patients with de novo MDS and different cyto-
morphologic subtypes, median survival was 122
months in patients with RA, 82 months in those with
RARS, 32 months in those with RCMD, and 43
months in those with RCMD-RS. Outcome did not
differ significantly between RA and RARS or between
RCMD and RCMD-RS.
The advanced MDS categories (eg, refractory
anemia with excess blasts (RAEB)-1 and -2 subtypes,
associated with a median OS of only 16 and 9
months, respectively [31]) remained unchanged in
the recent update of the classification system. The
WHO also introduced a heterogeneous category
termed ‘‘unclassifiable MDS’’ (MDS-U) that includes
patients with pancytopenia und unilineage dysplasia,
patients withRCUDorRCMDbutwith 1%of periph-
eral blasts, and patients with persistent cytopenia with-
out increased blasts but with evidence of clonal
cytogenetic abnormalities. Another recent change
was in the definition of the category ‘‘childhood
MDS’’ for pediatric patients under age 14 years. Ear-
lier, chronic myelomonocytic leukemia (CMML) had
been transferred from MDS to the ‘‘myelodysplastic/
myeloproliferative overlap’’ category [27].
In conclusion, cytomorphologic characteristics re-
main highly significant for the categorization of MDS
subtypes in the new WHO classification system. Fur-
thermore, they are highly relevant for the definition
of prognosis and thus also play an important role in
the decision for or against allo-SCT [2,27]. In a study
of 103 previously diagnosed low-risk MDS patients,
Howe et al. [32] found high interobserver congruence
for theWHO classification system, demonstrating the
practicability of the WHO system with respect to
cytomorphology.
Table 1. WHO Classification of MDS, 2008 [27]
Entity Dysplasia Blasts in Peripheral Blood Blasts in Bone Marrow Ring sideroblasts Cytogenetics
5q- syndrome Mostly dys-M < 1% < 5% <15% 5q- sole
RA, RN, RT, RCUD Dys-E, -N, -M < 1% < 5% <15% Various
RARS Mostly dys-E 0 < 5% >15% Various
RCMD 2-3 lineages Rare < 5% Various Various
RAEB-1 1-3 lineages <5% 5%-9% <15% Various
RAEB-2 1-3 lineages 5%-19% Auer rods +/- 10%-19% Auer rods +/- <15% Various
MDS-U 1 lineage <1% <5% <15% Various
Dys-E indicates, erythroid dypslasia; Dys-N, neutrophil dysplasia; Dys-M, dysplasia of megakaryocytes; MDS-U, unclassifiable myelodysplastic syndrome;
RA, refractory anemia; RAEB, refractory anemiawith excess blasts; RARS, refractory anemiawith ringed sideroblasts; RCMD, refractory cytopeniawith
multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; RN, refractory neutropenia; RT, refractory thrombocytopenia.
Table 2. Frequency of Selected Chromosomal Aberrations
and Median OS in De Novo MDS According to Haase [111]
Cytogenetic Abnormality Frequency, % Median OS, Months
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Chromosomal banding with the R-, G-, or
Q-technique provides an overview of the whole karyo-
type. To avoid overlooking small subclones, 20-25 BM
metaphases of good quality are required for valid re-
sults [33,34]. According to the recommendations of
the European Leukemia Network (ELN), perfor-
mance of at least 2 cultures (one for 24 hours and the
other for 48 hours) is recommended. BM should be
used for cytogenetics, because the cells from the
MDS clone usually do not proliferate in peripheral
blood (PB) [34,35]. The frequency of cytogenetic aber-
rations is 35% in early-stage de novo MDS, [36,37],
compared with 60%-65% in advanced/RAEB cases
[22,38]. The highest rates of cytogenetic aberrations
(. 90%) are seen in therapy-associated MDS
(t-MDS).
The most common abnormalities in MDS involve
chromosomes 5, 7, 20, and Y. These chromosomal
changes are all considered in the IPSS,which categorizes
MDS patients into 4 risk groups based on cytogenetics,
blast percentages, and the number of hematopoietic lin-
eages involved [19].However, cytogenetic risk grouping
remains one of the strongest determinants of prognosis
inMDS (Tables 2 and 3). In a recent large study of 1029
patients with de novo MDS, Pozdnyakova et al. [22]
found amedianOSof 64months in the good risk group,
comparedwith31months in the intermediate risk group
and 12months in the bad risk group.Haase et al. [20] re-
ported amedian survival of 53.4months for 612 patients
with normal karyotypes but of only 8.7 months for 166
patients with complex anomalies.del(12 p) 0.6 Not reached
+21 1.1 101
del(5q) 11 77
del(20q) 2 71
-X 0.5 56
Normal karyotype 52 53
-Y 2.8 39
-21 0.5 32
del(11q) 0.9 26
+8 5.3 23
del(7q) 0.9 19
Complex (3 anomalies) 2.7 17
-7 3.5 14
Complex (> 3 anomalies) 11 9
OS indicates overall survivall; MDS, myelodysplastic syndrome.Low-Risk Cytogenetics
Considering a cohort of unselected MDS patients,
those with a normal karyotype account for 40%-45%
of all cases and thus represent the largest low-risk
cytogenetic category. They show a rather favorable
outcome, with a median OS of .50 months [20].
The second largest group is those with interstitial ab-
normalities of 5q, which occur solely or in coincidence
with other abnormalities in 20%-25% of MDS cases
[20]. MDS with an isolated deletion of 5q with\5%of blasts in the BM and a unique cytomorphology
(the ‘‘5q- syndrome’’) represents 6% of de novo
MDS cases [38]. In most cases, the large interstitial
5q- deletion is revealed by chromosomal banding; in
most cases, in most cases breakpoints cluster at bands
5q13 and 5q33 [33,39]. Only 5%-15% of all cases of
5q- syndrome proceed to secondary AML (s-AML),
compared with 40% of all other MDS subtypes [40].
Although the classical 5q- syndrome is a clear do-
main for conservative treatment, including newer tar-
geted approaches such as lenalidomide [5,6], clinical
decision making is much more complex when the
del(5q) occurs in coincidence with other abnormali-
ties, as is seen in 20% of de novo MDS cases [41]. Gia-
gounidis et al. [42] reported a median survival of 47
months in patients with additional aberrations, in con-
trast to 127 months in those with isolated 5q- dele-
tions. An analysis of posttransplantation outcomes in
57 patients in different stages of MDS found a post-
transplantation relapse rate of 40% in cases where
the del(5q) was combined with other alterations versus
5% in cases of isolated del(5q) [21]. Cases with an iso-
lated del(5q), but an increased percentage of blasts
(. 5%) also carry an inferior prognosis [42]. These
findings illustrate the significance of the correct cyto-
genetic diagnosis in all cases of MDS with a del(5q)
Table 3. Cytogenetic Groups According to the IPSS [19] and the Studies of Sole et al. [36] and Haase et al. [20]
Risk group IPSS [19] Sole et al. [36] Haase et al. [20]
Favorable  Normal karyotype
 -Y, del(5q), and del(20q) as the
sole abnormalities
 Normal karyotype
 -Y, del(5q), del(20q), del(11q), and
del(12 p) as the sole abnormalities
 Normal karyotype
 -Y, del(5q), del(20q) +1/+1q, t(1q), t(7q),
del(9q), del(12 p), 15q-, t(15q), t(17q),
-21, +21, and -X in noncomplex
karyotypes
Intermediate Karyotypes belonging to neither the
favorable nor the unfavorable category
 3q21q26 rearrangements
 +8, +9, t(11q), del(17 p)
 3q2126 rearrangements
 +8, 11q-, abnormalities of
chromosome 19
 -7/7q-, -5
 3 clonal abnormalities
Unfavorable  Aberrations of chromosome 7
 Complex ($ 3 clonal aberrations)
 -7/7q-, i(17q)
 Complex ($ 3 clonal abnormalities)
 Translocations involving 5q
 Complex (> 3 clonal abnormalities)
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in therapeutic decision making.
Deletions of 20q —mostly in the q12 region—
occur in various myeloidmalignancies [43,44] and pre-
dict a favorable prognosis when they are the sole
abnormality inMDS. Del(20q) is frequently associated
with the RA or RARS subtype. The deletions are of
varying sizes and involve a common region in which
several tumor-suppressor genes are localized [43].
Brezinova et al. [45] investigated outcomes in 36 pa-
tients with MDS, AML, or a myeloproliferative neo-
plasm (MPN) and a del(20q) either by itself or in
combination with other abnormalities. Interestingly,
del(20q) in concert with other abnormalities had an ad-
verse impact on prognosis compared with an isolated
occurrence [46] independent of other relevant param-
eters, such as hematologic entity and age [45]. Com-
pared with normal del(20q) cases, isochromosome of
20q with loss of interstitial material, ider(20q), as
a rare variant of del(20q) has a worse prognosis [47].
Losses of the Y chromosome (which also can be
observed in healthy elderly male individuals) [33] and
isolated deletions of 12 p also have been linked to indo-
lent courses in MDS [22,38].
In a study of 2072 patients, Haase et al. [20] iden-
tified more abnormalities with a low incidence that
show a favorable prognosis when occurring as non-
complex aberrations: trisomy 1 or structural alter-
ations of chromosome 1q, reciprocal rearrangements
involving 7q, deletions of 9q, chromosome 15 abnor-
malities, translocations of 17q, numerical losses/gains
of chromosome 21, and -X. But, the favorable prog-
nostic impact of these rare abnormalities requires con-
firmation by additional studies, because conservative
treatment might be more suitable than an upfront
allo-SCT for these patients.Intermediate-Risk Cytogenetics
The most frequent cytogenetic abnormality with
an intermediate prognostic impact is trisomy 8. In de
novo MDS, 15%-20% of cases show this chromo-
somal aberration, as a sole anomaly in 8% of cases
[20,48]. A male predominance has been reported[49]. Some limited case series have associated trisomy
8 with an increased risk of leukemic transformation
[50], whereas others have reported very heterogeneous
outcomes, with a median survival of 19 months but
a range of 1-123 months in 1 study [22] and varying
transformation rates in another [51]. Consequently,
clearly defining therapeutic strategies in this subgroup
is a difficult task.
An intermediate prognosis has been described for
some rare abnormalities, including del(11q) and chro-
mosome 19 abnormalities occurring in non-complex
cases [20]. The clinical significance of del(11q) is under
debate; one study has suggested an association be-
tween isolated deletions of 11q23 and more favorable
outcomes, with a median survival of 53 months [22].
Interpretation of this cytogenetic alteration with
respect to the indication to allo-SCT remains difficult.
According to Sole et al. [36], cases involving trisomy 9
also should be included in the intermediate prognostic
group.Poor-Risk Cytogenetics
Loss of chromosome 7 and deletions of 7q are con-
sidered to compose a single category and to predict an
adverse prognosis [20]. These abnormalities are
detected in 15%-20% of all de novo MDS cases [19],
as an isolated abnormality in 8% [20]. Although
chromosome 7 abnormalities are detected mainly in
advanced MDS cases, they can occur at any stage of
the disease [33]. A median OS of 14 months has been
reported in noncomplex cases [20]. Interestingly, bet-
ter outcomes have been reported for patients with an
isolated del(7q) or derivative der(1;7)(q10;p10)
compared with those with a complete loss of
chromosome 7 [22].
Complex aberrant karyotypes are defined by the
existence of $3 clonal cytogenetic abnormalities.
These karyotypes occur primarily in advanced MDS
and carry an extremely adverse prognosis, with a me-
dian survival of \9 months [20]. Similarly, Haase
et al. [20] demonstrated a correlation between progno-
sis and the extent of complexity.Whereas patients with
3 abnormalities had median survival of 17 months,
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months, and those with .10 anomalies had a median
survival of only 4 months. Frequently, complex aber-
rant karyotypes are associated with deletions of the
TP53 tumor-suppressor gene, which is localized on
17p13. Unbalanced translocations with numerical or
structural gains or losses in noncomplex karyotypes
also are prognostically adverse [33].
Isochromosome i(17q) has been linked to myelo-
proliferative features and poor response to therapy
[52], with a median OS of only 10 months [22]. Trans-
locations involving the 5q region also have been
reported to confer an adverse prognosis [20].
Compared with de novo MDS, t-MDS has a very
high frequency of cytogenetic aberrations (up to
90%). The recently modified WHO classification sys-
tem introduced the category of ‘‘therapy-related mye-
loid neoplasms,’’ which incorporates various
myelogenous malignancies, including AML, MDS,
and the MDS/MPN (myeloproliferative/myelodys-
plastic) overlap category with an association with pre-
vious therapy with alkylating agents, topoisomerase
inhibitors, or radiation [27]. Unfavorable cytogenetics
are more frequent in treatment-associated myeloge-
nous malignancies [53] with higher percentages of,
for example, chromosome 7 aberrations. In an analysis
of 306 consecutive patients with t-MDS/t-AML,
Smith et al. [54] detected chromosome 7 abnormalities
in 28% of the patients, chromosome 5 aberrations in
21%, and both aberrations in 22%. However, within
distinct cytogenetic risk groups, posttransplantation
outcomes were equivalent in patients with t-MDS
and those with de novo MDS [55].FLUORESCENCE IN SITU HYBRIDIZATION
Classical chromosome banding analyses require
cultivation of vital mitotic cells. Because of the limited
resolution, cryptic deletions or rearrangements cannot
be detected with this technique. Complex aberrations
and the exact breakpoints of deletions often cannot
be fully clarified. Difficulties also can arise from low-
quality BM metaphases, a lack of proliferating
malignant cells, or technical difficulties, such as
a long transport time [39]. Thus, in some cases chro-
mosomal banding analysis is complemented by diverse
molecular cytogenetic techniques. FISH can be per-
formed on interphase nuclei (IP-FISH) or on meta-
phase chromosomes (MP-FISH). Single-locus as well
as whole chromosome probes (ie, whole chromosome
painting) can be used. Twenty-four–color FISH
(multiplex [M-FISH]/spectral karyotyping [SKY]) is
suitable for illustrating the whole karyotype. These
techniques are based on the detection of fluores-
cence-labeled DNA probes to define chromosomal
alterations and allow the identification of complexaberrant rearrangements, precise breakpoints, or mi-
nor abnormal clones with greater sensitivity and spec-
ificity [56,57].
IP-FISH allows the analysis of 100-200 cells, offer-
ing considerably enhanced sensitivity compared with
classical chromosomal banding analyses [34]. The
technique can be performed with locus-specific probes
or probes for the centromer regions on metaphases, as
well as on interphase nuclei, without the need for vital
cells. It should be kept inmind, however, that IP-FISH
can detect only those specific genetic aberrations for
which the probes are designed [41]. Finally, the indi-
vidual cutoff defined by the sensitivity of the probe
must be considered [34,35] to avoid detection of non-
specific background.
M-FISH/SKY simultaneously reveals all numeri-
cal and structural rearrangements in a metaphase.
Twenty-four different chromosome painting probes
are obtained from degenerated oligonucleotide PCR.
Panels of 5 fluorochromes are used in combinatorially
labeled chromosome painting probes. This is helpful
for clarifying complex aberrations or marker chromo-
somes. But, this technique has limited applications be-
cause of, for example, differences in the legibility of
fluorochromes and in the sizes of the translocated
chromosomal segments [58].
Specific Indications for FISH
For identification of a del(5q), probes are commer-
cially available for the EGR1 gene on the 5q31.2 locus,
as well as for other loci, such as CSF1R on 5q33-34 or
telomeric-specific regions of 5q [56,59]. In cases of sus-
pected 5q- syndrome due to, for example, the presence
of characteristic microkaryocytes, IP-FISH should be
performed even if cytogenetics show a normal karyo-
type, to identify occasional cryptic 5q- deletions [39].
With M-FISH, many del(5q) cases have been found
to represent not ‘‘pure’’ deletions, but rather unbal-
anced translocations leading to derivative chromo-
somes in association with a del(5q) [58,60]. Thus,
cases with atypical 5q- deletions or cases with suspected
other aberrations besides the del(5q) might be evalu-
ated with M-FISH, because the involvement of other
chromosomal regions or other chromosomes is associ-
ated with an inferior prognosis compared with ‘‘pure’’
5q- deletions [16,17]. M-FISH/SKY can clarify MDS
cases with complex aberrations [61-64]. Complex
aberrant cases can involve different subclones.
Hidden Cytogenetic Abnormalities in Normal-
Karyotype MDS Detectable by FISH
Clonal chromosomal abnormalities are found in up
to 50% of patients with primary MDS; however, the
rate of cytogenetic abnormalities actually may be
higher, because of underestimation of aberration rates
by the chromosome banding technique. Thus, it has
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cell populations or cryptic abnormalities [65]. Some
studies have reported the detection of hidden aberra-
tions of chromosomes 5, 7, and 8 with IP-FISH in
10-15% of MDS patients with an apparently normal
karyotype as assessed with chromosomal banding [65-
67]. In some of these patients, the results of FISH anal-
ysis led to a change in the IPSS score to a worse prog-
nostic group [65,68]. Aberrations detected solely by
FISH have less prognostic power than those revealed
by chromosomal banding, however [53]. It remains to
be clarified whether such hidden abnormalities play
a relevant role inMDS, for example, in the case of a hid-
den monosomy 7 with its adverse prognostic impact
[67]. So far, there are no recommendations whether
such hidden abnormalities should be considered in
therapeutic decisions and whether IP-FISH should
be used as a complementary tool in patients with a nor-
mal karyotype [65].
Absence of Karyotyping Results
Because of the central role of abnormalities of
chromosomes 5, 7, and Y and a complex aberrant kar-
yotype in the IPSS [19], these aberrations should be
screened by FISH in the event of suboptimal cytoge-
netics [69]. One comparison of chromosome banding
analysis and IP-FISH in 48 patients with mostly lower
advanced-stage MDS showed that the 2 techniques
had similar sensitivity in bone marrow aspirates; the
cytogenetic abnormality rate was 37% with chromo-
some banding and 35% with IP-FISH [69].
According to the ELN proposal, FISH assays in-
cluding probes for detecting aberrations of chromo-
somes/chromosomal regions 5q, 7, 7q, 8, 20q, 17p13,
and Y should be performed, because these detect the
most common abnormalities [34,35]. However, IP-
FISH detects only a subset of aberrations that can be
identified by chromosome banding analysis, and in
particular, complex aberrant karyotypes will be under-
estimated if only IP-FISH can be performed.MOLECULAR GENETICS
Around 40%-45% of all MDS cases exhibit a nor-
mal karyotype [36] and would benefit greatly from fur-
ther molecular subclassification. Compared with
AML, for which PCR can successfully characterize
85% of cases with a normal karyotype, recurrent mo-
lecular markers have been identified in only a low per-
centage of MDS patients to date.
The most frequent mutations in MDS are point
mutations of theAML1/RUNX1 gene, located at chro-
mosome band 21q22. This gene encodes a protein that
heterodimerizes with core-binding factor beta to form
the core-binding factor complex, a transcription factor
for hematopoietic development. Relevant mutationsresult in missense, nonsense, and frame shift
mutations. Harada et al. [70] identified AML1 muta-
tions in 24% of 110 cases of MDS RAEB or s-AML.
These mutations were associated with an adverse
prognosis and apparently were related to transforma-
tion to s-AML [70]. It has been hypothesized that
the loss of function of a singleAML1 allele confers sus-
ceptibility to the acquisition of secondary mutations
and cytogenetic alterations [71]. Thus, screening for
the respective molecular marker in cases of RAEB-1
or -2 might be considered, because positive results
could predict a rapid progression to s-AML [72].
The prognostically adverse FLT3-ITD (internal
tandem duplications in the juxtamembranous domain
of the FLT3 class-III-receptor tyrosine kinase) are
far less frequent in MDS than in AML [73,74]; how-
ever, leukemic transformation of MDS was accompa-
nied by FLT3-ITD acquisition in$10% of all cases
in one study [75]. Detection of FLT3-ITD at the
time of diagnosis ofMDS is associated with higher leu-
kemic transformation rates and shorter survival [75].
Mutations of the NRAS protooncogene also show
an increased frequency from the initial stage to the
advanced stages in MDS [76,77].
Occasionally, FLT3-TKD (mutations of the FLT3
activation loop), MLL-PTD (intragenic duplications
of the MLL gene), and KIT mutations have been de-
scribed in MDS [77], and mutations of the NPM1
gene [78] have been found in single cases as well [79].
Thus, analysis for gene mutations will be informative
in a relevant percentage of MDS cases, especially dur-
ing the course of the disease, because these mutations
can indicate a high risk of transformation to AML.
This might support earlier SCT. Further studies in
this area are urgently needed.
Finally, the JAK2V617F mutation is rare in MDS,
with a frequency of only 5% [80]. In contrast, there is
a high frequency in RARS associated with marked
thrombocytosis (RARS-T) and 5q-syndromes, both
of which carry a favorable prognosis. Furthermore,
JAK2V617F mutations are detectable in 5%-10% of
CMML cases [81] and are found in varying frequencies
in other MDS/MPN overlap syndromes [27,44] with
more heterogeneous clinical profiles [44,81,82].
Thus, the finding of JAK2V617F in a case previously
classified as MDS should always raise the possibility
that a categorization within the MDS/MPN category
may be more appropriate.WT1 EXPRESSION
Overexpression of the Wilms’ tumor-suppressor
(WT1) gene is found in various hematologic malignan-
cies [83-85]. Expression levels of this gene seem to be
an appropriate parameter for monitoring response to
therapy in myelogenous malignancies [86-89]. In
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increase during leukemic transformation and to de-
crease following chemotherapy or SCT [91]. Quanti-
tative real-time PCR can measure WT1 expression
with a sensitivity of 1024; however, problems can arise
due to the physiological background expression of
WT1 in healthy individuals.
In a large series of MDS patients, Cilloni and
Saglio [87] found WT1 expression above the range
seen in normal control samples.WT1 levels were corre-
lated with the type ofMDS and the IPSS score. Tamaki
et al. [91] reported that WT1 levels increased signifi-
cantly with disease progression and could predict leu-
kemic transformation within 6 months. These
findings suggest that longitudinal monitoring ofWT1
levels might be useful in detecting MDS progression
and identifying patients at high risk for progression.
To date, there are no standard recommendations for
integratingWT1 levels in therapeutic decision making
or in the indications for allo-SCT in MDS.MULTIPARAMETER FLOW CYTOMETRY
In recent years, multiparameter flow cytometry
(MFC) has found application in MDS diagnosis and
follow-up investigations. Besides quantifying myelo-
blasts, this technique can detect aberrant antigen
expression on granulocytes, monocytes, and erythro-
cytes. Aberrant patterns on myeloblasts include
expression of CD11b, which is normally limited toma-
ture cells, and the lymphoid and natural killer cell
markers CD19, CD7, CD5, and CD56, whereas
HLA-DR (which is regularly found on blasts) may be
absent.Granulocytes are frequently observedwith a re-
duced side-scatter signal because of reduced granular-
ity coming along with dysgranulopoiesis. CD13 and
CD16 may be expressed in an aberrant pattern
[18,92], and expression of the panleukocyte antigen
CD45 often is reduced [18,41,93]. Erythrocytes can
be characterized by a lack of CD71 expression
[93,94]. Aberrant expression of the CD7 antigen on
the myeloid blasts in RAEB has been associated with
a worse prognosis [95,96].
Truong et al. [97] reported a predictive value of
69% for a diagnosis of MDS in cytopenic patients
when flow cytometric analysis showed aberrant anti-
gen expression patterns in myelogenous and mono-
cytic cells. Based on phenotypic and scatter
characteristics, flow cytometric scoring systems have
been developed that allow for a simple numerical dis-
play of results [18]. In a study in 113 patients with
MDS, Wells et al. [18] described a direct correlation
of flow cytometry scores (FCSS) with IPSS scores
and IPSS cytogenetic risk categories (P\ .1). A second
analysis from this group found a cumulative incidence
of 3-year posttransplantation relapse of 15%, 10%,
and 36% in MDS patients with mild, moderate, andsevere FCSS scores, respectively [98]. The FCSS score
was predictive of posttransplantation outcomes even
after adjusting for risk factors such as myeloblast
percentages and the IPSS score [98]. Veltroni et al.
[96] have demonstrated the applicability of flow
cytometry scores in pediatric patients with MDS.
Standardization of the use of MFC in diagnosing
MDS is currently underway through an initiative of
the ELN [99]. In the near future, it should be possible
to incorporate FCSS scores in determining the indica-
tions for SCT.SIGNIFICANCE OF PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
SUBCLONES
Patients suffering from aplastic anemia (AA) often
exhibit a minor population of paroxysmal nocturnal he-
moglobinuria (PNH)-type cells.Wang et al. [100] stud-
ied 164patientswithMDS for the presence of these cells
and discovered a significant increase in 18% of patients
with RA and in 13% of patients with overall MDS. Pa-
tients with higher levels of PNH-type cells had a higher
incidence of severe thrombocytopenia, a lower rate of
transformation to s-AML, and a higher response rate
to cyclosporine (CsA) therapy compared with PNH-
negative patients at the same stage of MDS. These pa-
tients also had a lower rate of cytogenetic anomalies.
This suggests that an increased number of PNH-type
cells might be associated with a benign type of BM fail-
ure. PNH screening by MFC for all MDS patients has
been proposed [100]. Because of the favorable
response to immunosuppression, whether such a strat-
egy should be tested in all respective cases before
planning of allo-SCT should be evaluated.DEFINITION OF REMISSION IN MDS
An international working group has proposed stan-
dard criteria for the assessment of remission in MDS
[101]. These criteria comprise morphological, cytoge-
netic, and hematologic parameters and also take into
account the clinical condition (Table 4). Such stan-
dardization of the response to conservative treatment
can be helpful in determining whether a patient might
benefit from the continuation of conservative treat-
ment or whether referral to SCT should be considered.DISCUSSION
Regardless of the recent advances in the subclassifi-
cation of MDS cases and in more detailed prognostic
predictions, the timing of and indications for allo-SCT
remain difficult in many cases [14]. Although the IPSS
is extremely helpful in clinical decision making in
Table 4. Criteria for Assessing Remission in MDS According to an International Working Group [101]
Criteria of remission Parameters
Morphological and hematologic response Complete remission: bone marrow blasts <5% without dysplasia, hemoglobin $11 g/dL,
platelets $100 109/L, neutrophils $1.5 109/LPartial remission: reduction of blasts by at least
50% or achievement of lower risk category than before treatment
Cytogenetic response Major cytogenetic response: disappearance of a cytogenetic abnormality; Minor cytogenetic
response: $ 50% reduction of abnormal metaphases
Quality of life Clinical improvement in physical/social function and well being
Hematologic improvement Specific responses of cytopenias in the 3 hematopoietic lineages
8 Biol Blood Marrow Transplant 16:1-11, 2010U. Bacher et al.MDS[12,102], it cannot cover thewhole spectrumof cy-
togenetic abnormalities. Thus, the diversity of cytoge-
netic abnormalities as demonstrated in the studies of
Sole et al. [36] and Haase et al. [20], which take combi-
nations of cytogenetic abnormalities as well as rare cyto-
genetic subgroups into account, is not represented in
this scoring system as it was originally published in
1997. To improve the categorization of prognostically
relevant subgroups of the IPSS, new cytogenetic sub-
groups have been proposed [103]. Moreover, variances
in clinical outcome exist evenwithin distinct cytogenetic
subgroups.
It remains to be clarified whether FISH screening
for hidden cytogenetic abnormalities in normal karyo-
type cases [65-67] or for more complex cytogenetic
aberrations (eg, a 5q-deletion) [58,60] might help better
describe the prognosis inMDSandmake indications for
SCTmore transparent. The major goals are to identify
patients at greater risk for transformation and to make
more detailed predictions within distinct cytogenetic
subgroups. The presence of molecular mutations in,
for example, the AML1 gene might be prognostically
relevant inanother subsetofpatientswithnormal karyo-
type [70], who might need earlier SCT; however, PCR
screening in MDS is not yet standardized.
The WHO classification system [27] provides
a more homogeneous morphological categorization
with respect to cytogenetic risk groups and prognosis
compared with the FAB system [26]. Thus, to improve
prognostic predictions, the suggestion was made to
combine the WHO and IPSS systems in a new
‘‘WPSS’’ (WHO classification–based prognostic scor-
ing system), which also incorporates transfusion de-
pendence [104]. Based on a retrospective study of
106 MDS patients, Cermak et al. [105] suggested
that combined WHO morphology and IPSS cytoge-
netic criteria could be helpful in, for example, identify-
ing high-risk patients in the RA group who should
proceed without delay to SCT. Also, in del(5q) pa-
tients, the WPSS more clearly predicted outcome
compared with the IPSS [106]. Alessandrino et al.
[107] confirmed that both theWHO classification sys-
tem and the WPSS have good prediction accuracy for
OS and the probability of posttransplantation relapse.
Considering that the IPSS cannot reflect all of the de-
tails of the morphological WHO classification system,
this combined WPSS approach might be superior toevaluation of the IPSS alone in the planning of thera-
peutic strategies. Therefore, incorporation of the
IPSS/WPSS and the WHO classification system in
transplantation algorithms is currently under discus-
sion [108]. Additional tools, including the FCSS [18],
require further validation before they can contribute
to risk assessment in the indications for allo-SCT.
It must be mentioned that other parameters besides
a more exact risk stratification also may be relevant to the
timing of allo-SCT [14]. Delay of SCTmay be associated
with an increased accumulation of iron, worsening the
prognosis [109] or leading to the development of comor-
bidities. Thus, the exclusion of poor prognostic features,
such as older age, from the IPSS also should be considered
in the decision for or against immediate allo-SCT [14].
Finally, the growing arsenal of pharmacotherapeutic
approaches (eg, lenalidomide, azacytidine, antithymocyte
globulin [ATG]) for certain MDS subgroups also might
influence the timing of allo-SCT [3,15].
In conclusion, our findings indicate that risk assess-
ment and the indication and timing for allo-SCT in
patients with MDS might benefit from a wider spec-
trum of methods, including cytomorphology, cytoge-
netics, FISH, flow cytometry, and molecular genetics
specifically for advanced MDS cases. Moreover, novel
techniques, such as microarray-based gene expression
profiling, also might promote risk stratification in
MDS. For example, theMicroarray Innovations inLeu-
kemia study group has developed a diagnostic classifica-
tion model able to distinguish cases with an ‘‘AML call’’
with a high risk of rapid leukemic transformation to
s-AML within 18 months from cases with a benign
hematologic disorder mimicking MDS (neither MDS
nor AML) with a more indolent course [110]. Such
novel technologies alsomight help optimize therapeutic
decisions in MDS and aid in the development of diag-
nostic algorithms aimed at helping clinicians to identify
the most appropriate MDS patients for SCT as well as
the most appropriate timing of the procedure.ACKNOWLEDGMENTS
Financial disclosure: C. Haferlach, S. Schnittger,
W. Kern, and T. Haferlach declare ownership of
the MLL Munich Leukemia Laboratory. U. Bacher,
N. Kro¨ger, and A.R. Zander have no interests to
disclose.
Biol Blood Marrow Transplant 16:1-11, 2010 9Diagnostics in the Indication for Allo-SCT in MDSREFERENCES
1. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping
with ineffective hematopoiesis.NEngl JMed. 2005;352:536-538.
2. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors
and life expectancy in myelodysplastic syndromes classified ac-
cording to WHO criteria: a basis for clinical decision making.
J Clin Oncol. 2005;23:7594-7603.
3. Mufti GJ, ChenTL. Changing the treatment paradigm inmye-
lodysplastic syndromes. Cancer Control. 2008;15(Suppl):14-28.
4. Hofmann WK, Heil G, Zander C, et al. Intensive chemother-
apy with idarubicin, cytarabine, etoposide, andG-CSF priming
in patients with advanced myelodysplastic syndrome and high-
risk acute myeloid leukemia. Ann Hematol. 2004;83:498-503.
5. Beran M. Intensive chemotherapy for patients with high-risk
myelodysplastic syndrome. Int J Hematol. 2000;72:139-150.
6. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelo-
dysplastic syndrome with chromosome 5q deletion. N Engl J
Med. 2006;355:1456-1465.
7. Gratwohl A, Schmid O, Baldomero H, et al. Haematopoietic
stem cell transplantation (HSCT) in Europe 2002: changes in
indication and impact of team density. A report of the EBMT
activity survey. Bone Marrow Transplant. 2004;34:855-875.
8. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and
syngeneic marrow transplantation for myelodysplastic syn-
drome in patients 55 to 66 years of age. Blood. 2000;95:
1188-1194.
9. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem
cell transplantation after a fludarabine/busulfan-based re-
duced-intensity conditioning in patients with myelodysplastic
syndrome or secondary acute myeloid leukemia. Ann Hematol.
2003;82:336-342.
10. Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regi-
men intensity on outcome of allogeneic hematopoietic cell
transplantation for advanced acute myelogenous leukemia
and myelodysplastic syndrome. Biol Blood Marrow Transplant.
2006;12:1047-1055.
11. DeegHJ. Transplant strategies for patients with myelodysplas-
tic syndromes. Curr Opin Hematol. 2006;13:61-66.
12. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of
allogeneic bone marrow transplantation for the myelodysplas-
tic syndromes: delayed transplantation for low-risk myelodys-
plasia is associated with improved outcome. Blood. 2004;104:
579-585.
13. De Witte T, Hermans J, Vossen J, et al. Haematopoietic stem
cell transplantation for patients with myelodysplastic syn-
dromes and secondary acute myeloid leukaemias: a report on
behalf of the Chronic Leukaemia Working Party of the Euro-
pean Group for Blood and Marrow Transplantation (EBMT).
Br J Haematol. 2000;110:620-630.
14. Oliansky DM, Antin JH, Bennett JM, et al. The role of cyto-
toxic therapy with hematopoietic stem cell transplantation in
the therapy of myelodysplastic syndromes: an evidence-based
review. Biol Blood Marrow Transplant. 2009;15:137-172.
15. Itzykson R, Fenaux P. Optimal sequencing of treatments for
patients with myelodysplastic syndromes. Curr Opin Hematol.
2009;16:77-83.
16. Cermak J, Michalova K, Brezinova J, et al. A prognostic impact
of separation of refractory cytopenia with multilineage dyspla-
sia and 5q- syndrome from refractory anemia in primary mye-
lodysplastic syndrome. Leuk Res. 2003;27:221-229.
17. Goasguen JE. Is it still possible to ameliorate the diagnosis of
refractory anemia? Leuk Res. 2003;27:201-203.
18. Wells DA, Benesch M, Loken MR, et al. Myeloid and mono-
cytic dyspoiesis as determined by flow cytometric scoring in
myelodysplastic syndrome correlates with the IPSS and with
outcome after hematopoietic stem cell transplantation. Blood.
2003;102:394-403.
19. Greenberg P, Cox C, LeBeau MM, et al. International scoring
system for evaluating prognosis in myelodysplastic syndromes.
Blood. 1997;89:2079-2088.20. Haase D, Germing U, Schanz J, et al. New insights into the
prognostic impact of the karyotype in MDS and correlation
with subtypes: evidence from a core dataset of 2124 patients.
Blood. 2007;110:4385-4395.
21. Stewart B, Verdugo M, Guthrie KA, et al. Outcome following
haematopoietic cell transplantation in patients with myelodys-
plasia and del (5q) karyotypes.Br JHaematol. 2003;123:879-885.
22. Pozdnyakova O,Miron PM, TangG, et al. Cytogenetic abnor-
malities in a series of 1,029 patients with primarymyelodysplas-
tic syndromes: a report from the US with a focus on some
undefined single chromosomal abnormalities. Cancer. 2008;
113:3331-3340.
23. Raj K, Mufti GJ. Azacytidine (Vidaza) in the treatment of
myelodysplastic syndromes. Ther Clin Risk Manag. 2006;2:
377-388.
24. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in
TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-2301.
25. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mu-
tations in TET2 are common in myelodysplastic syndromes.
Nat Genet. 2009;41:838-842.
26. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the
classification of the myelodysplastic syndromes. Br J Haematol.
1982;51:189-199.
27. Swerdlow S, Campo E, Lee Harris N, et al.WHO Classification
of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition.
Lyon, France: WHO Press; 2008.
28. Germing U, Strupp C, Kuendgen A, et al. Prospective valida-
tion of the WHO proposals for the classification of myelodys-
plastic syndromes. Haematologica. 2006;91:1596-1604.
29. Breccia M, Mengarelli A, Mancini M, et al. Myelodysplastic
syndromes in patients under 50 years old: a single-institution
experience. Leuk Res. 2005;29:749-754.
30. Navarro I, RuizMA, Cabello A, et al. Classification and scoring
systems in myelodysplastic syndromes: a retrospective analysis
of 311 patients. Leuk Res. 2006;30:971-977.
31. Germing U, Strupp C, Kuendgen A, et al. Refractory anaemia
with excess of blasts (RAEB): analysis of reclassification accord-
ing to the WHO proposals. Br J Haematol. 2006;132:162-167.
32. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO
classification of MDS does make a difference. Blood. 2004;
103:3265-3270.
33. Bernasconi P, Boni M, Cavigliano PM, et al. Clinical relevance
of cytogenetics in myelodysplastic syndromes. Ann N Y Acad
Sci. 2006;1089:395-410.
34. Valent P, Horny HP, Bennett JM, et al. Definitions and stan-
dards in the diagnosis and treatment of the myelodysplastic
syndromes: consensus statements and report from a working
conference. Leuk Res. 2007;31:727-736.
35. Haferlach C, Rieder H, Lillington DM, et al. Proposals for
standardized protocols for cytogenetic analyses of acute leuke-
mias, chronic lymphocytic leukemia, chronic myeloid
leukemia, chronic myeloproliferative disorders, and myelodys-
plastic syndromes. Genes Chromosomes Cancer. 2007;46:494-
499.
36. Sole F, Luno E, Sanzo C, et al. Identification of novel cytoge-
netic markers with prognostic significance in a series of 968
patients with primary myelodysplastic syndromes.
Haematologica. 2005;90:1168-1178.
37. Fenaux P. Chromosome and molecular abnormalities in mye-
lodysplastic syndromes. Int J Hematol. 2001;73:429-437.
38. Sole F, Espinet B, Sanz GF, et al. Incidence, characterization
and prognostic significance of chromosomal abnormalities in
640 patients with primary myelodysplastic syndromes. Grupo
Cooperativo Espanol de Citogenetica Hematologica. Br J
Haematol. 2000;108:346-356.
39. Zou YS, Fink SR, Stockero KJ, et al. Efficacy of conventional
cytogenetics and FISH for EGR1 to detect deletion 5q in he-
matological disorders and to assess response to treatment
with lenalidomide. Leuk Res. 2007;31:1185-1189.
40. Giagounidis AA, Germing U, Haase S, et al. Clinical, morpho-
logical, cytogenetic, and prognostic features of patients with
10 Biol Blood Marrow Transplant 16:1-11, 2010U. Bacher et al.myelodysplastic syndromes and del(5q) including band q31.
Leukemia. 2004;18:113-119.
41. Cherian S, Bagg A. The genetics of the myelodysplastic syn-
dromes: classical cytogenetics and recent molecular insights.
Hematology. 2006;11:1-13.
42. Giagounidis AA, Germing U, Strupp C, et al. Prognosis of
patients with del(5q)MDS and complex karyotype and the pos-
sible role of lenalidomide in this patient subgroup. Ann Hema-
tol. 2005;84:569-571.
43. Douet-Guilbert N, Basinko A, Morel F, et al. Chromosome 20
deletions in myelodysplastic syndromes and Philadelphia chro-
mosome–negative myeloproliferative disorders: characteriza-
tion by molecular cytogenetics of commonly deleted and
retained regions. Ann Hematol. 2008;87:537-544.
44. Bacher U. Schnittger S. Kern W. et al. Distribution of cytoge-
netic abnormalities in myelodysplastic syndromes, Philadel-
phia-negative myeloproliferative neoplasms, and the overlap
MDS/MPN category Ann Hematol In Press.
45. Brezinova J, Zemanova Z, Ransdorfova S, et al. Prognostic sig-
nificance of del(20q) in patients with hematological malignan-
cies. Cancer Genet Cytogenet. 2005;160:188-192.
46. Liu YC, Ito Y, Hsiao HH, et al. Risk factor analysis in myelo-
dysplastic syndrome patients with del(20q): prognosis revisited.
Cancer Genet Cytogenet. 2006;171:9-16.
47. Douet-Guilbert N, Lai JL, Basinko A, et al. Fluorescence in
situ hybridization characterization of ider(20q) in myelodys-
plastic syndrome. Br J Haematol. 2008;143:716-720.
48. PaulssonK, Sall T, FioretosT, et al. The incidence of trisomy 8
as a sole chromosomal aberration in myeloid malignancies
varies in relation to gender, age, prior iatrogenic genotoxic ex-
posure, and morphology. Cancer Genet Cytogenet. 2001;130:
160-165.
49. Pedersen B.MDS and AMLwith trisomy 8 as the sole chromo-
some aberration show different sex ratios and prognostic pro-
files: a study of 115 published cases. Am J Hematol. 1997;56:
224-229.
50. De Souza FT, OrnellasMH, Otero de Carvalho L, et al. Chro-
mosomal alterations associated with evolution from myelodys-
plastic syndrome to acute myeloid leukemia. Leuk Res. 2000;24:
839-848.
51. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognos-
tic significance of karyotype abnormalities in de novo primary
myelodysplastic syndromes: a study on 331 patients from a sin-
gle institution. Leukemia. 2005;19:1424-1431.
52. Sole F, Torrabadella M, Granada I, et al. Isochromosome 17q
as a sole anomaly: a distinct myelodysplastic syndrome entity?
Leuk Res. 1993;17:717-720.
53. Steensma DP, List AF. Genetic testing in the myelodysplastic
syndromes: molecular insights into hematologic diversity.
Mayo Clin Proc. 2005;80:681-698.
54. Smith SM, Le BeauMM,HuoD, et al. Clinical–cytogenetic as-
sociations in 306 patients with therapy-related myelodysplasia
and myeloid leukemia: the University of Chicago series. Blood.
2003;102:43-52.
55. Armand P, KimHT, DeAngelo DJ, et al. Impact of cytogenet-
ics on outcome of de novo and therapy-related AML andMDS
after allogeneic transplantation. Biol Blood Marrow Transplant.
2007;13:655-664.
56. Herry A, Douet-Guilbert N, Morel F, et al. Redefining mono-
somy 5 by molecular cytogenetics in 23 patients with MDS/
AML. Eur J Haematol. 2007;78:457-467.
57. Halling KC, Kipp BR. Fluorescence in situ hybridization in
diagnostic cytology. Hum Pathol. 2007;38:1137-1144.
58. Shali W, Helias C, Fohrer C, et al. Cytogenetic studies of
a series of 43 consecutive secondary myelodysplastic syn-
dromes/acute myeloid leukemias: conventional cytogenetics,
FISH, and multiplex FISH. Cancer Genet Cytogenet. 2006;168:
133-145.
59. Bigoni R, Cuneo A, Milani R, et al. Multilineage involvement
in the 5q- syndrome: a fluorescent in situ hybridization study
on bone marrow smears. Haematologica. 2001;86:75-81.60. Lindvall C, Nordenskjold M, Porwit A, et al. Molecular cyto-
genetic characterization of acute myeloid leukemia and myelo-
dysplastic syndromes with multiple chromosome
rearrangements. Haematologica. 2001;86:1158-1164.
61. Babicka L, Ransdorfova S, Brezinova J, et al. Analysis of com-
plex chromosomal rearrangements in adult patients with MDS
and AML by multicolor FISH. Leuk Res. 2007;31:39-47.
62. Martinez-Ramirez A, Urioste M, Alvarez S, et al. Cytogenetic
profile of myelodysplastic syndromes with complex karyotypes:
an analysis using spectral karyotyping. Cancer Genet Cytogenet.
2004;153:39-47.
63. Barouk-Simonet E, Soenen-CornuV, Roumier C, et al. Role of
multiplex FISH in identifying chromosome involvement in
myelodysplastic syndromes and acute myeloid leukemias with
complex karyotypes: a report on 28 cases. Cancer Genet Cytoge-
net. 2005;157:118-126.
64. Trost D, Hildebrandt B, Beier M, et al. Molecular cytogenetic
profiling of complex karyotypes in primary myelodysplastic
syndromes and acutemyeloid leukemia.Cancer.GenetCytogenet.
2006;165:51-63.
65. Bernasconi P, Cavigliano PM, Boni M, et al. Is FISH a relevant
prognostic tool in myelodysplastic syndromes with a normal
chromosome pattern on conventional cytogenetics? A study
on 57 patients. Leukemia. 2003;17:2107-2112.
66. Panani AD, Pappa V. Hidden chromosome 8 abnormalities
detected by FISH in adult primary myelodysplastic syndromes.
In Vivo. 2005;19:979-981.
67. Trost D,Hildebrandt B,Muller N, et al. Hidden chromosomal
aberrations are rare in primarymyelodysplastic syndromeswith
evolution to acute myeloid leukaemia and normal cytogenetics.
Leuk Res. 2004;28:171-177.
68. Rigolin GM, Bigoni R, Milani R, et al. Clinical importance
of interphase cytogenetics detecting occult chromosome
lesions in myelodysplastic syndromes with normal karyotype.
Leukemia. 2001;15:1841-1847.
69. Cherry AM, Brockman SR, Paternoster SF, et al. Comparison
of interphase FISH and metaphase cytogenetics to study mye-
lodysplastic syndrome: an Eastern Cooperative Oncology
Group (ECOG) study. Leuk Res. 2003;27:1085-1090.
70. HaradaH,Harada Y,NiimiH, et al. High incidence of somatic
mutations in the AML1/RUNX1 gene in myelodysplastic syn-
drome and low–blast percentagemyeloid leukemia withmyelo-
dysplasia. Blood. 2004;103:2316-2324.
71. Hellstrom-Lindberg E, Willman C, Barrett AJ, et al. Achieve-
ments in understanding and treatment of myelodysplastic syn-
dromes. Hematology (Am Soc Hematol Educ Program). 2000;(1):
110-132.
72. Dicker F,HaferlachC, KernW, et al.Mutations in normal kar-
yotype AML cooperate with class I mutations in the progres-
sion to s-AML following MDS. ASH Annual Meeting, 2008.
Blood. 2008. 112, 924.
73. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3
length mutations in 1003 patients with acute myeloid
leukemia: correlation to cytogenetics, FAB subtype, and prog-
nosis in the AMLCG Study and usefulness as a marker for the
detection of minimal residual disease. Blood. 2002;100:59-66.
74. Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance
of FLT3 internal tandem duplication and tyrosine kinase do-
main mutations for acute myeloid leukemia: a meta-analysis.
Leukemia. 2005;19:1345-1349.
75. Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or
N-ras mutations is frequently associated with progression of
myelodysplastic syndrome to acute myeloid leukemia.
Leukemia. 2004;18:466-475.
76. Mitani K, Hangaishi A, Imamura N, et al. No concomitant oc-
currence of theN-ras and p53 gene mutations in myelodysplas-
tic syndromes. Leukemia. 1997;11:863-865.
77. Bacher U, Haferlach T, Kern W, et al. A comparative study of
molecular mutations in 381 patients with myelodysplastic
syndrome and in 4130 patients with acute myeloid leukemia.
Haematologica. 2007;92:744-752.
Biol Blood Marrow Transplant 16:1-11, 2010 11Diagnostics in the Indication for Allo-SCT in MDS78. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophos-
min in acute myelogenous leukemia with a normal karyotype.
N Engl J Med. 2005;352:254-266.
79. Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelo-
dysplastic syndromes and acute myeloid leukemia with normal
karyotype. Leuk Res. 2007;31:109-111.
80. SteensmaDP, DewaldGW, LashoTL, et al. The JAK2 V617F
activating tyrosine kinase mutation is an infrequent event in
both ‘‘atypical’’ myeloproliferative disorders andmyelodysplas-
tic syndromes. Blood. 2005;106:1207-1209.
81. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F
activating mutation occurs in chronic myelomonocytic leuke-
mia and acutemyeloid leukemia, but not in acute lymphoblastic
leukemia or chronic lymphocytic leukemia. Blood. 2005;106:
3377-3379.
82. SzpurkaH, Tiu R, Murugesan G, et al. Refractory anemia with
ringed sideroblasts associated with marked thrombocytosis
(RARS-T), another myeloproliferative condition characterized
by JAK2 V617F mutation. Blood. 2006;108:2173-2181.
83. Miwa H, Beran M, Saunders GF. Expression of the Wilms’
tumor gene (WT1) in human leukemias. Leukemia. 1992;6:
405-409.
84. Miyagi T, Ahuja H, Kubota T, et al. Expression of the candi-
date Wilm’s tumor gene, WT1, in human leukemia cells.
Leukemia. 1993;7:970-977.
85. InoueK,OgawaH, Sonoda Y, et al. Aberrant overexpression of
theWilms’ tumor gene (WT1) in human leukemia. Blood. 1997;
89:1405-1412.
86. Cilloni D, Gottardi E, DeMicheli D, et al. Quantitative assess-
ment ofWT1 expression by real-time quantitative PCRmay be
a useful tool for monitoring minimal residual disease in acute
leukemia patients. Leukemia. 2002;16:2115-2121.
87. Cilloni D, Saglio G. WT1 as a universal marker for minimal
residual disease detection and quantification in myeloid leuke-
mias and in myelodysplastic syndrome. Acta Haematol. 2004;
112:79-84.
88. Shimoni A, Nagler A. Clinical implications of minimal residual
disease monitoring for stem cell transplantation after reduced-
intensity and nonmyeloablative conditioning. Acta Haematol.
2004;112:93-104.
89. WeisserM, KernW, Rauhut S, et al. Prognostic impact of RT-
PCR–based quantification of WT1 gene expression during
MRD monitoring of acute myeloid leukemia. Leukemia.
2005;19:1416-1423.
90. Bader P, Niemeyer C, Weber G, et al. WT1 gene expression:
useful marker for minimal residual disease in childhoodmyelo-
dysplastic syndromes and juvenile myelo-monocytic leukemia?
Eur J Haematol. 2004;73:25-28.
91. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor
gene, WT1, is a good marker for diagnosis of disease
progression of myelodysplastic syndromes. Leukemia. 1999;
13:393-399.
92. Lorand-Metze I, Califani SM, Ribeiro E, et al. The prognostic
value of maturation-associated phenotypic abnormalities in
myelodysplastic syndromes. Leuk Res. 2008;32:211-213.
93. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic
utility of flow cytometric immunophenotyping in myelodys-
plastic syndrome. Blood. 2001;98:979-987.
94. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytom-
etry evaluation of erythroid dysplasia in patients with myelo-
dysplastic syndrome. Leukemia. 2006;20:549-555.
95. Ogata K, Nakamura K, YokoseN, et al. Clinical significance of
phenotypic features of blasts in patients with myelodysplastic
syndrome. Blood. 2002;100:3887-3896.96. Veltroni M, Sainati L, Zecca M, et al. Advanced pediatric mye-
lodysplastic syndromes: can immunophenotypic characteriza-
tion of blast cells be a diagnostic and prognostic tool? Pediatr
Blood Cancer. 2009;52:357-363.
97. Truong F, Smith BR, Stachurski D, et al. The utility of flow cy-
tometric immunophenotyping in cytopenic patients with
a non-diagnostic bone marrow: a prospective study. Leuk Res.
2009;33:1039-1046.
98. Scott BL, Wells DA, Loken MR, et al. Validation of a flow
cytometric scoring system as a prognostic indicator for post-
transplantation outcome in patients with myelodysplastic syn-
drome. Blood. 2008;112:2681-2686.
99. Van de Loosdrecht A, Alhan C, Bene MC, et al. Standardiza-
tion of flow cytometry in myelodysplastic syndromes: report
from the first ELNet working conference on flow cytometry
in MDS. Haematologica. 2009;94:1124-1134.
100. WangH,ChuhjoT,YasueS,et al.Clinical significanceof aminor
population of paroxysmal nocturnal hemoglobinuria-type cells in
bone marrow failure syndrome. Blood. 2002;100:3897-3902.
101. Cheson BD,Greenberg PL, Bennett JM, et al. Clinical applica-
tion and proposal for modification of the International Work-
ing Group (IWG) response criteria in myelodysplasia. Blood.
2006;108:419-425.
102. Armand P, Kim HT, Cutler CS, et al. A prognostic score for
patients with acute leukemia or myelodysplastic syndromes un-
dergoing allogeneic stem cell transplantation. Biol Blood Mar-
row Transplant. 2008;14:28-35.
103. Bernasconi P, Klersy C, Boni M, et al. World Health Organi-
zation classification in combination with cytogenetic markers
improves the prognostic stratification of patients with de
novo primary myelodysplastic syndromes. Br J Haematol.
2007;137:193-205.
104. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent
prognostic scoring system for predicting survival and leukemic
evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:
3503-3510.
105. Cermak J, Vitek A,MichalovaK. Combined stratification of re-
fractory anemia according to bothWHO and IPSS criteria has
a prognostic impact and improves identification of patients
who may benefit from stem cell transplantation. Leuk Res.
2004;28:551-557.
106. Tasaka T, Tohyama K, Kishimoto M, et al. Myelodysplastic
syndromewith chromosome 5 abnormalities: a nationwide sur-
vey in Japan. Leukemia. 2008;22:1874-1881.
107. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO
classification and WPSS predict posttransplantation outcome
in patients with myelodysplastic syndrome: a study from the
Gruppo Italiano Trapianto diMidollo Osseo (GITMO). Blood.
2008;112:895-902.
108. Kindwall-Keller T, Isola LM. The evolution of hematopoietic
SCT in myelodysplastic syndrome. Bone Marrow Transplant.
2009;43:597-609.
109. Kataoka K, Nannya Y, Hangaishi A, et al. Influence of pre-
transplantation serum ferritin on nonrelapse mortality after
myeloablative and nonmyeloablative allogeneic hematopoietic
stem cell transplantation. Biol Blood Marrow Transplant. 2009;
15:195-204.
110. Mills KI, Kohlmann A, Williams PM, et al. Microarray-
based classifiers and prognosis models identify subgroups
with distinct clinical outcomes and high risk of AML trans-
formation of myelodysplastic syndrome (MDS). Blood.
2009. 114:1063–1072.
111. Haase D. Cytogenetic features in myelodysplastic syndromes.
Ann Hematol. 2008;87:515-526.
